A randomised controlled clinical study to evaluate the efficacy of vastyamayantaka ghrita uttara basti in the management of vatashteela(Benign prostatic hyperplasia)
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 40
- 试验地点
- 1
研究概览
简要总结
Benign prostatic hyperplasia is benign enlargement of prostate and affects both glandular
epithelium and connective tissue stroma. It presents with features of incomplete emptying of urine,
urgency, hesitancy, increased frequency and difficulty in micturition. It is a disease process with a
well defined age incidence and occurs after 50 years. The prevalence of Benign Prostatic Hyperplasia
increases after the age of 40 years, with a prevalence of 8percent to 60percent at the age of 90 years.
In Ayurveda, Mutraghata is considered as Mutravarodha. It occurs due to Pratiloma gati of
vata dosha in basti resulting in avarodha of Mutravaha srotas. It causes Vibandhata, Krichrata and
Alpata of mutra. Acharya Sushruta has explained Mutraghata in Uttara tantra and symptoms of
Mutraghata specifically Vatashteela can be closely resembled to Benign Prostatic Hyperplasia.
In contemporary science use of Tamsulosin (5 a Blocker) is mentioned as one of the
conservative management of Benign Prostatic Hyperplasia which are having side effects like
orthostatic hypotension, dizziness, depression and gynaecomastia. Trans Urethral Resection of
Prostate (TURP) is the primary surgical approach for Benign Prostatic Hyperplasia which has
postoperative complications like hemorrhage, recurrence erectile dysfunction, urethral stricture, etc.
Under these circumstances, it is a great need of hour to introduce novel, cost effective, safe
and effective treatment modalities to treat the patients of Benign Prostatic Hyperplasia. In
Mutraghata chikitsa, Acharya Sushruta, in Uttara tantra has mentioned Uttara basti as one of the
prime treatment for the management of Mutraghata and he has also mentioned use of Kashaya,
Kalka, Ghrita etc. which are having properties of Mutrala and Kaphamedahara. In Sahasrayoga
Ghrita prakarana, Vastyamayantaka ghrita has been indicated in all types of Mutraghata by
providing VataPittahara karma by the virtue of combination of ingredients present in It. Hence
Vastyamayantaka ghrita is taken for Uttara basti over Tamsulosin in the management o f Mutraghata
(Vatashteela).
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 50.00 Year(s) 至 80.00 Year(s)（—）
- 性别
- Male
入选标准
- •Patient with signs and symptoms of Vatashteela (Benign Prostatic Hyperplasia) and IPSS (International Prostate Symptom Score ) less than
- •Patient with age group between 50 t o 80 years.
- •USG o f Abdomen and pelvis prostate suggestive o f increased weight upto 80gm Patient who willing t o give written Informed consent were included in the study.
排除标准
- •Patients with malignancy of prostate will be excluded.
- •Patients with severe urinary tract infection, urethral stricture will be excluded.
- •Patients with severe cardio vascular, renal or hepatic disorders.
- •Hypertension (more than 160 100mmHg) & Diabetes mellitus (RBS more than 250mgdl) are excluded.
- •Patients with immune compromised diseases will be excluded.
- •Patients with US findings suggestive of Hydroureteronephrosis are excluded.
- •PSA valuve more than 4ngdl.
研究者
Dr Pavan Janagond
Shri Jagadguru Gavisiddeshwar Ayurvedic Medical College Koppal